E. Michalis

发表

High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents

M. Dimopoulos, T. Economopoulos, A. Symeonidis, 2010, European journal of haematology.

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group

M. Dimopoulos, E. Kastritis, M. Gavriatopoulou, 2018, Blood Cancer Journal.

Identi ﬁ cation of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP

Theodoros, G. Tsourouflis, S. Papageorgiou, 2021 .

Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience

M. Dimopoulos, E. Kastritis, M. Gavriatopoulou, 2015, Annals of Hematology.

Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis

G. Vassilopoulos, K. Konstantopoulos, M. Angelopoulou, 2018, Hematological oncology.

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

M. Dimopoulos, P. Sonneveld, P. Morel, 2013, Blood.

A very rare case of extranodal B-cell non-Hodgkin lymphoma presenting with adrenal and heart involvement

L. Papanastasiou, T. Choreftaki, A. Perpinia, 2022, Leukemia research reports.

Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study

G. Pangalis, E. Hatjiharissi, M. Gavriatopoulou, 2020, Journal of clinical medicine.

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration

M. Dimopoulos, E. Kastritis, E. Katodritou, 2009, Haematologica.

A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis.

M. Dimopoulos, E. Kastritis, M. Gavriatopoulou, 2012, Blood.

Primary Renal Lymphoma Presenting with Chronic Low-Grade Fever

N. Anagnostopoulos, A. Zomas, E. Michalis, 2004, International journal of hematology.

The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD‐EPI‐CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD‐EPI‐CysC equations?

I. Papassotiriou, E. Kastritis, E. Katodritou, 2013, European journal of haematology.

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

M. Dimopoulos, P. Sonneveld, P. Morel, 2017, Blood.

No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

M. Dimopoulos, K. Konstantopoulos, T. Economopoulos, 2010, American journal of hematology.

CLINICAL TRIALS OBSERVATIONS BDR in newly diagnosed patients with WM: ﬁ nal analysis of a phase 2 study after a minimum follow-up of 6 years

M. Dimopoulos, P. Sonneveld, P. Morel, 2017 .

Prognostication of the high-risk WM patient.

M. Dimopoulos, K. Konstantopoulos, T. Economopoulos, 2011, Clinical Lymphoma, Myeloma & Leukemia.

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study

M. Dimopoulos, E. Kastritis, M. Gavriatopoulou, 2012 .

Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network

M. Dimopoulos, P. Sonneveld, P. Morel, 2009 .

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group

M. Dimopoulos, E. Kastritis, M. Gavriatopoulou, 2014, American journal of hematology.

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post‐bortezomib monotherapy

E. Kastritis, E. Katodritou, E. Terpos, 2012, International journal of cancer.

Circulating angiopoietin‐1 to angiopoietin‐2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents

M. Dimopoulos, E. Kastritis, E. Katodritou, 2012, International journal of cancer.

Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era

M. Dimopoulos, E. Hatzimichael, E. Kastritis, 2012, European journal of haematology.

Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group

M. Dimopoulos, K. Konstantopoulos, E. Hatzimichael, 2011 .

Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies

M. Dimopoulos, S. Giannouli, E. Hatzimichael, 2017, European journal of haematology.

High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma.

M. Dimopoulos, E. Kastritis, M. Gavriatopoulou, 2009 .

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience

M. Angelopoulou, G. Pangalis, M. Kyrtsonis, 2017, Hematological oncology.

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group

M. Dimopoulos, E. Kastritis, M. Gavriatopoulou, 2018, Blood Cancer Journal.

Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma ≥80 Years of Age: An Analysis of the Greek Myeloma Study Group

M. Dimopoulos, E. Hatzimichael, E. Kastritis, 2011 .

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

M. Dimopoulos, P. Sonneveld, P. Morel, 2017, Blood.

The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function.

M. Dimopoulos, K. Konstantopoulos, T. Economopoulos, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.